- Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
- Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
- European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot
- Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
- Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023
- Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
- Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
- Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
- Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
- Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
More ▼
Key statistics
As of last trade Scinai Immunotherapeutics Ltd (SCNI:NAQ) traded at 3.48, 8.92% above its 52-week low of 3.20, set on May 21, 2024.
52-week range
Open | 3.77 |
---|---|
High | 3.77 |
Low | 3.48 |
Bid | 3.45 |
Offer | 3.60 |
Previous close | 3.44 |
Average volume | 7.24k |
---|---|
Shares outstanding | 1.45k |
Free float | -- |
P/E (TTM) | -- |
Market cap | 2.00m USD |
EPS (TTM) | -2.31 USD |
Data delayed at least 15 minutes, as of May 23 2024 15:16 BST.
More ▼